公开(公告)号：US20170081301A1

公开(公告)日：2017-03-23

申请号：US15306971

申请日：2015-04-22

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Min LI ,  Zhaobing GAO ,  Yangming ZHANG ,  Haining HU ,  Haiyan XU ,  Huanan LIU ,  Xiaoping PI

IPC: C07D307/24 ,  C07C237/48 ,  C07C275/64 ,  C07C235/16 ,  C07C271/28 ,  C07C333/08

CPC classification number: C07D307/24 ,  A61K31/167 ,  A61K31/17 ,  A61K31/27 ,  A61K31/277 ,  A61K31/341 ,  C07C231/02 ,  C07C233/62 ,  C07C235/16 ,  C07C235/74 ,  C07C237/04 ,  C07C237/22 ,  C07C237/48 ,  C07C269/04 ,  C07C269/06 ,  C07C271/28 ,  C07C273/18 ,  C07C275/64 ,  C07C333/08 ,  C07C2601/02 ,  C07C2601/14

Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.